Top Story

EXSCEL: Exenatide meets primary safety objective for CV risk in type 2 diabetes

May 23, 2017

Top-line results from the EXSEL trial show the GLP-1 receptor agonist exenatide extended release met the primary safety objective of non-inferiority for major adverse cardiac events in patients with type 2 diabetes when compared with placebo, Astra Zeneca announced in a press release.

The Exenatide Study of Cardiovascular Event Lowering trial compared the effect of once-weekly exenatide extended release (Bydureon) added to usual care with placebo on the risk for the composite endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke, in adults with type-2 diabetes at a wide range of CV risk. The EXSCEL trial is the largest and most inclusive patient population of any CV outcomes trial of the GLP-1 receptor agonist class conducted to date, including more than 14,000 patients from 35 countries, according to the release.

Meeting News

New therapies offer options for patients with diabetes, heart failure

May 6, 2017
AUSTIN, Texas — New anti-diabetic therapies offer options for patients with type 2 diabetes and heart failure, whereas several ongoing and longer-term studies are…
Meeting News

Resveratrol may reduce arterial stiffness in patients with diabetes

May 5, 2017
Resveratrol reversed arterial stiffness in patients with type 2 diabetes, according to an abstract presented at the American Heart Association’s Arteriosclerosis…

Trial to study subcutaneous ICD in patients with diabetes, MI commences

April 29, 2017
An international trial to study the survival benefit of a subcutaneous implantable cardioverter defibrillator system has begun enrolling patients, according to a press…
In the Journals Plus

Weight loss at 1 year predicts sustained benefit, lower HbA1c in diabetes, obesity

January 6, 2017
Patients with diabetes and obesity who lose at least 7% of their body weight at 1 year are more likely to sustain that weight loss at 5 years along…

In the Journals

Metformin may reduce mortality in patients with certain chronic diseases

January 6, 2017
Recent changes in metformin labeling by the FDA is supported by new findings published in Annals of Internal Medicine that suggest that patients…

Cardiology Today's Top 10 articles posted in 2016

January 6, 2017
Cardiology Today compiled a list of the top 10 stories posted to Healio.com/Cardiology in 2016. This year, Cardiology Today’s readers…

In the Journals

BVS shows efficacy, safety in patients with diabetes

January 5, 2017
An everolimus-eluting bioresorbable vascular scaffold appears to be safe and effective in patients with diabetes, particularly those with baseline…

In the Journals

Younger patients with severe dyslipidemia less likely to receive statins

January 5, 2017
The statin prescription rate for patients with severe dyslipidemia is 66%, with age being the most important predictor, as younger patients are less…

FDA News

CV data added to labels for treatments containing empagliflozin

January 5, 2017
The FDA recently approved supplemental New Drug Applications for type 2 diabetes treatments that include empagliflozin to add in results from the…

Cardiology Today’s top 5 articles posted in December

January 3, 2017
 Cardiology Today compiled a list of the top 5 stories posted to Healio.com/Cardiology in December.

In the Journals

Fenofibrate therapy may reduce CVD risk in some patients with diabetes

December 29, 2016
The risk for CVD may be reduced with the use of fenofibrate therapy in patients with type 2 diabetes, hypertriglyceridemia and low HDL, according to…

AMA releases seven health recommendations for 2017

December 28, 2016
As 2017 is quickly approaching, the AMA announced vital topics and recommendations that physicians should discuss with their patients to help ensure…

In the JournalsPerspective

New review on dietary sugar guidelines sparks debate

December 27, 2016
Research findings suggest that the current guideline recommendations for sugar intake are not based on high-quality evidence and thus are not

More Headlines »